Over the last decades, major advances in the molecular profiling of acute myeloid leukaemia (AML) led to a deeper understanding of its pathophysiology and revealed potential therapeutic opportunities. As a result, the classification of AML subtypes has evolved from a morphological to a molecular and genetic basis. After years of stagnation, we recently witnessed a rapid expansion of the therapeutic armamentarium in this disease. Therefore, Professor Sébastien Anguille from Antwerp University Hospital gave an overview of the recent advances in this setting. On the other side, in acute lymphoblastic leukaemia (ALL), about half of the adult patients who do not achieve a complete molecular response or who subsequently relapse cannot be cured with the current chemotherapy and targeted agents. In recent years, different immune-based therapies emerged, including monoclonal antibodies, bispecific antibodies, CAR-T cell therapy and antibody drug conjugates. These new treatment options were discussed by Professor Nicolas Boissel from the Saint-Louis Hospital in Paris, France.
